deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT00676845

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Conditions Hypertension Metabolic Syndrome
Interventions olmesartan medoxomil placebo
Updated 11 times since 2017 Last updated: Dec 20, 2018 Started: Aug 31, 2008 Primary completion: May 31, 2011 Completion: May 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertension and Metabolic Syndrome and is currently completed. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotCompleted~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshotCompleted~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2024 · 38 months · monthly snapshotCompleted~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Mar 2024 [monthly]

    Completed PHASE3

▶ Show 6 earlier versions

  1. Jan 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jul 2018 — Jan 2019 [monthly]

    Completed PHASE3

  3. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

  4. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE3

  5. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE3

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations